RE:Vote YES? NO?
Vote Yes...
Player, it is unfortunate that after 4 months the new CEO has been unable to provide the slightest tangible evidence that Urocidin is anything but a waste of 150 mil.
He has discussed its potential but there hasn't been a shred evidence of interest in it since it was discarded by Endo.
We have heard about the 30 plus interested parties and major pharmas and all the rest of it. The problem is that we heard the same about Animal Health and we are seeing how that turned out.
To his credit at least he hasn't pulled out the Paladin/Endo throw in as an indication of its value. I am still not convinced Paladin/Endo are even aware that they own the Urocidin rights to the 3 countries that they do. I invested more in a coffee and bagel this am than this rights holder will in Urocidin's upcoming trials.
He might as well publicly pronounce its value at 30 billion. To this shareholder base talk is less than cheap.